Literature DB >> 20534857

Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Susana Guerra1, José Manuel González, Núria Climent, Hugh Reyburn, Luis A López-Fernández, José L Nájera, Carmen E Gómez, Felipe García, José M Gatell, Teresa Gallart, Mariano Esteban.   

Abstract

The aim of this study was to define the effects on antigen-presenting cells of the expression of HIV antigens from an attenuated poxvirus vector. We have analyzed the transcriptional changes in gene expression following infection of human immature monocyte-derived dendritic cells (DC) with recombinant modified vaccinia virus Ankara (MVA) expressing the genes encoding the gp120 and Gag-Pol-Nef antigens of HIV type 1 clade B (referred to as MVA-B) versus parental MVA infection. Using microarray technology and real-time reverse transcription-PCR, we demonstrated that the HIV proteins induced the expression of cytokines, cytokine receptors, chemokines, chemokine receptors, and molecules involved in antigen uptake and processing, including major histocompatibility complex (MHC) genes. Levels of mRNAs for interleukin-1, beta interferon, CCR8, and SCYA20 were higher after HIV antigen production. MVA-B infection also modulated the expression of antigen processing and presentation genes: the gene for MICA was upregulated, whereas those for HLA-DRA and HSPA5 were downregulated. Indeed, the increased expression of the gene for MICA, a glycoprotein related to major histocompatibility complex class I molecules, was shown to enhance the interaction between MVA-B-infected target cells and cytotoxic lymphocytes. The expression profiles of the genes for protein kinases such as JAK1 and IRAK2 were activated after HIV antigen expression. Several genes included in the JAK-STAT and mitogen-activated protein kinase signaling pathways were regulated after HIV antigen expression. Our findings provide the first gene signatures in DC of a candidate MVA-B vaccine expressing four HIV antigens and identified the biological roles of some of the regulatory genes, like that for MICA, which will help in the design of more effective MVA-derived vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534857      PMCID: PMC2916545          DOI: 10.1128/JVI.00749-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells.

Authors:  M L Albert; M Jegathesan; R B Darnell
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

Review 3.  Natural killer cells: a mystery no more.

Authors:  L Moretta; R Biassoni; C Bottino; M C Mingari; A Moretta
Journal:  Scand J Immunol       Date:  2002-03       Impact factor: 3.487

4.  HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication.

Authors:  Claudia Cicala; James Arthos; Sara M Selig; Glynn Dennis; Douglas A Hosack; Donald Van Ryk; Marion L Spangler; Tavis D Steenbeke; Prateeti Khazanie; Neil Gupta; Jun Yang; Marybeth Daucher; Richard A Lempicki; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

5.  Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Alberto Pascual-Montano; José Luis Nájera; Angel Zaballos; Mariano Esteban
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.

Authors:  T J Blanchard; A Alcami; P Andrea; G L Smith
Journal:  J Gen Virol       Date:  1998-05       Impact factor: 3.891

7.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation.

Authors:  H Hsu; J Xiong; D V Goeddel
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

8.  Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Raquel Conde; Alberto Pascual-Montano; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

Review 10.  The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

Authors:  Carmen E Gómez; José L Nájera; Magdalena Krupa; Mariano Esteban
Journal:  Curr Gene Ther       Date:  2008-04       Impact factor: 4.391

View more
  17 in total

1.  The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Authors:  Carmen Elena Gómez; José Luis Nájera; Beatriz Perdiguero; Juan García-Arriaza; Carlos Oscar S Sorzano; Victoria Jiménez; Rubén González-Sanz; José Luis Jiménez; María Angeles Muñoz-Fernández; Juan Carlos López Bernaldo de Quirós; Alberto C Guardo; Felipe García; José M Gatell; Montserrat Plana; Mariano Esteban
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

2.  Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

Authors:  Juan García-Arriaza; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

3.  Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.

Authors:  Xiaoying Shen; Ryan Duffy; Robert Howington; Alethea Cope; Shanmugalakshmi Sadagopal; Haesun Park; Ranajit Pal; Suefen Kwa; Song Ding; Otto O Yang; Genevieve G Fouda; Roger Le Grand; Diane Bolton; Mariano Esteban; Sanjay Phogat; Mario Roederer; Rama R Amara; Louis J Picker; Robert A Seder; M Juliana McElrath; Susan Barnett; Sallie R Permar; Robin Shattock; Anthony L DeVico; Barbara K Felber; George N Pavlakis; Giuseppe Pantaleo; Bette T Korber; David C Montefiori; Georgia D Tomaras
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

4.  Extracellular Vesicles and Their Use as Vehicles of Immunogens.

Authors:  Chiara Chiozzini; Barbara Ridolfi; Maurizio Federico
Journal:  Methods Mol Biol       Date:  2022

5.  Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

Authors:  Juan García-Arriaza; José Luis Nájera; Carmen E Gómez; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-08-24       Impact factor: 3.240

6.  Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

Authors:  Juan García-Arriaza; Pilar Arnáez; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

7.  Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.

Authors:  Núria Climent; Susana Guerra; Felipe García; Cristina Rovira; Laia Miralles; Carmen Elena Gómez; Núria Piqué; Cristina Gil; José María Gatell; Mariano Esteban; Teresa Gallart
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

8.  A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

Authors:  Juan García-Arriaza; José Luis Nájera; Carmen E Gómez; Nolawit Tewabe; Carlos Oscar S Sorzano; Thierry Calandra; Thierry Roger; Mariano Esteban
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

9.  Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Victoria Jiménez; Abdelali Filali-Mouhim; Khader Ghneim; Elias K Haddad; Esther D Quakkelaar; Esther D Quakkerlaar; Julie Delaloye; Alexandre Harari; Thierry Roger; Thomas Duhen; Thomas Dunhen; Rafick P Sékaly; Cornelis J M Melief; Thierry Calandra; Federica Sallusto; Antonio Lanzavecchia; Ralf Wagner; Giuseppe Pantaleo; Mariano Esteban
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

10.  Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.

Authors:  Magali Matsumiya; Elena Stylianou; Kristin Griffiths; Zoe Lang; Joel Meyer; Stephanie A Harris; Rosalind Rowland; Angela M Minassian; Ansar A Pathan; Helen Fletcher; Helen McShane
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.